Last reviewed · How we verify
M lymphoplasmacytic
Approved treatments
- Imbruvica · AbbVie
Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells. - Imbruvica · Rabin Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- M lymphoplasmacytic patent landscape — cliff calendar, originator estates, attackable patents
- M lymphoplasmacytic treatment landscape brief
- M lymphoplasmacytic treatment updates RSS
Frequently asked questions about M lymphoplasmacytic
What drugs treat M lymphoplasmacytic?
Tracked treatments include Imbruvica.
What is the treatment for M lymphoplasmacytic?
Standard treatment for M lymphoplasmacytic includes Imbruvica. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: M lymphoplasmacytic patent cliff · M lymphoplasmacytic CI report
- Treatment: Imbruvica · AbbVie
- Treatment: Imbruvica · Rabin Medical Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing